Helen Binang

Dr. Helen Binang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HBHelen Binang
Helen Binang
CPChamini Perera
Chamini Perera
MAMinoti Vivek Apte
Minoti Vivek Apte
One of the most common and deadly types of pancreatic cancer (PC) is pancreatic ductal adenocarcinoma (PDAC), with most patients succumbing to the disease within one year of diagnosis. Current detection strategies do not address asymptomatic PC; therefore, patients are diagnosed at an advanced stage when curative treatment is often no longer possible. In order to detect PC in asymptomatic patients earlier, the risk factors that could serve as reliable markers need to be examined. Diabetic mellitus (DM) is a significant risk factor for this malignancy and can be both a cause and consequence of PC. Typically, DM caused by PC is known as new-onset, pancreatogenic, pancreoprivic, or pancreatic cancer-related diabetes (PCRD). Although PCRD is quite distinct from type 2 DM (T2DM), there are currently no biomarkers that differentiate PCRD from T2DM. To identify such biomarkers, a better understanding of the mechanisms mediating PCRD is essential. To this end, there has been a growing research interest in recent years to elucidate the role of tumour-derived exosomes and their cargo in the pathogenesis of PCRD. Exosomes derived from tumours can be recognized for their specificity because they reflect the characteristics of their parent cells and are important in intercellular communication. Their cargo consists of proteins, lipids, and nucleic acids, which can be transferred to and alter the behaviour of recipient cells. This review provides a concise overview of current knowledge regarding tumour-derived exosomes and their cargo in PCRD and discusses the potential areas worthy of further study.

24 July 2026 in African Journal of Urology
Verified
Journal Article
Open access
PDF file
GIGrace Chika Igebu
Grace Chika Igebu
OMOluwatosin Franscica Mabadeje
Oluwatosin Franscica Mabadeje
CEChinaza Enyinnaya-Okidi
Chinaza Enyinnaya-Okidi
HBHelen Binang
Helen Binang
EAEnosakhare Aiyudubie Asemota
Enosakhare Aiyudubie Asemota
IIIjeoma Promise Ikeji
Ijeoma Promise Ikeji
Background: Prostate cancer remains a leading cause of cancer morbidity and mortality among men globally, with the highest death rates observed in low- and middle-income countries (LMICs). Although therapeutic advances have substantially improved outcomes in high-income settings, their impact in LMICs has been limited by late presentation, diagnostic constraints, restricted access to effective treatments, and health system fragility. Metastatic prostate cancer therefore dominates clinical practice in many LMICs, necessitating context-adapted diagnostic and management strategies. Methods: This narrative review synthesizes evidence from population-level datasets, international clinical trials, observational studies, and global oncology policy literature to examine the diagnosis and management of metastatic prostate cancer in low- and middle-income countries, with particular emphasis on sub-Saharan Africa where the burden of late-stage disease and the implementation constraints are most consistently documented. Evidence was selected for clinical relevance, feasibility, and health system applicability rather than for statistical pooling. Results: Across many LMIC settings, 40–70% of men with prostate cancer present with metastatic disease at diagnosis, contributing to five-year survival rates below 40%, compared with over 90% in many high-income countries. Diagnostic pathways are constrained by limited access to Prostate-Specific Antigen (PSA) testing, pathology services, conventional imaging, and advanced staging technologies, necessitating risk-stratified and symptom-directed approaches. In metastatic castration-sensitive prostate cancer, reliable androgen deprivation therapy remains the treatment foundation, with surgical orchiectomy offering a durable and cost-effective option where medical castration is unaffordable or unreliable. Docetaxel provides meaningful survival benefit in selected fit patients but requires minimum supportive care capacity, while access to androgen receptor pathway inhibitors remains highly variable. In metastatic castration-resistant disease, most patients depend on chemotherapy, symptom control, and palliative care. Cross-cutting barriers include financial toxicity, workforce shortages, fragmented referral pathways, and unreliable medicine supply chains. Nonetheless, implementation models from several LMICs demonstrate measurable improvements in access, continuity of care, and affordability through integrated financing, task-shifting, and centralized procurement. Conclusion: Outcomes for men with metastatic prostate cancer in LMICs are shaped more by health system capacity than by therapeutic efficacy alone. The evidence supports a tiered approach that prioritizes timely diagnosis, uninterrupted androgen deprivation therapy, selective treatment intensification, and accessible palliative care. Lessons from sub-Saharan Africa show that measurable gains are achievable through task-sharing, simplified referral pathways, centralized procurement, and financial protection for essential cancer services.

1 May 2026 in Sustainability
Verified
Journal Article
Open access
PDF file
Opeyemi Deji-OloruntobaOpeyemi Deji-Oloruntoba
Opeyemi Deji-Oloruntoba
AOAdefarati Oloruntoba
Adefarati Oloruntoba
HBHelen Binang
Helen Binang
OOOlusanya Olasehinde
Olusanya Olasehinde
Climate change is increasingly recognized as a source of psychological distress, yet the prevalence, predictors, and behavioral implications of climate anxiety remain unevenly understood. This study examines climate anxiety, its key drivers, and associated behavioral responses in a multi-country sample of adults. A cross-sectional online survey was conducted across 21 countries using the Climate Change Anxiety Scale (CCAS), alongside measures of awareness, coping strategies, social support, and food-related behaviors, including food waste reduction, increased plant-based food consumption, and home or community gardening. Analyses included descriptive statistics, exploratory factor analysis (EFA), and multivariable regression. Given the uneven country-level representation, results are reported as pooled patterns with a few exploratory cross-country comparisons. Climate anxiety was widely reported, with over 60% of participants indicating that climate challenges were emotionally overwhelming. Regression analyses showed that climate awareness and frequency of climate-related thinking were positively associated with higher anxiety, although the effect sizes were small and explanatory power was limited (R2 = 0.055). EFA identified two related dimensions: cognitive concern about future impacts and affective distress. Climate anxiety across countries showed modest variation (2.44–3.23) and no statistically significant differences, despite variation in awareness. A gap between concern and climate action was evident: only 39.1% reported environmentally motivated dietary changes. Cost, limited availability, and lack of information were the main barriers to climate action, and only 24.4% reported frequent social support. These findings indicate that climate anxiety is shaped by both psychological and structural factors, and that reducing it requires not only increasing awareness but also enabling conditions that support meaningful climate action.